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Design: Two-staged, cross-sectional clinical study in 17 centers (Norway, Sweden, and 
Germany). Residual glucocorticoid (GC) production was defined as quantifiable serum cortisol 
and 11-deoxycortisol and residual mineralocorticoid (MC) production as quantifiable serum 
aldosterone and corticosterone after > 18 hours of medication fasting. Corticosteroids were 
analyzed by liquid chromatography–tandem mass spectrometry. Clinical variables included 
frequency of adrenal crises and quality of life. Peak cortisol response was evaluated by a 
standard 250 µg cosyntropin test.
Results: Fifty-eight (30.2%) of 192 patients had residual GC production, more common in men 
(n = 33; P < 0.002) and in shorter disease duration (median 6 [0-44] vs 13 [0-53] years; P < 0.001). 
Residual MC production was found in 26 (13.5%) patients and associated with shorter disease 
duration (median 5.5 [0.5-26.0] vs 13 [0-53] years; P < 0.004), lower fludrocortisone replacement 
dosage (median 0.075 [0.050-0.120] vs 0.100 [0.028-0.300] mg; P < 0.005), and higher plasma 
renin concentration (median 179 [22-915] vs 47.5 [0.6-658.0] mU/L; P < 0.001). There was no 
significant association between residual production and frequency of adrenal crises or quality 
of life. None had a normal cosyntropin response, but peak cortisol strongly correlated with 
unstimulated cortisol (r = 0.989; P < 0.001) and plasma adrenocorticotropic hormone (ACTH; 
r = –0.487; P < 0.001).
Conclusion: In established AAD, one-third of the patients still produce GCs even decades after 
diagnosis. Residual production is more common in men and in patients with shorter disease 
duration but is not associated with adrenal crises or quality of life. (J Clin Endocrinol Metab 105: 
2430–2441, 2020)
Key Words:  Adrenal failure; adrenal steroids; Autoimmune Addison disease; cortisol; primary 
adrenal insufficiency; residual function
Autoimmune Addison disease (AAD) is generally considered to be irreversible, inevitably leading to 
total destruction of the functional adrenal cortex (1). 
However, increasing evidence indicates that a subgroup 
of patients retain some level of corticosteroid produc-
tion even after many years of disease duration.
In 2011, Smans and Zelissen found quantifiable base-
line cortisol levels in 7 of 27 patients with established 
AAD, measured in a medication fasting state (2). More 
recently, Vulto et  al reported measurable levels of the 
cortisol precursor, 11-deoxycortisol, in 8 of 20 patients 
with primary adrenal insufficiency (3). Efforts to ex-
ploit residual production therapeutically have demon-
strated partial improvement in peak cortisol response to 
cosyntropin stimulation testing in 7 of 13 patients with 
newly diagnosed AAD after 12 weeks combined treat-
ment with rituximab and depot tetracosactide (4). In 4 
of these patients, stimulated serum cortisol exceeded 
100 nmol/L after 72 weeks. At study start, these 4 pa-
tients had higher mean stimulated cortisol levels, but 
did otherwise not differ from the 9 other patients.
Up until now, studies have been performed only in 
small cohorts, and the clinical relevance of residual 
production has not yet been addressed. Residual gluco-
corticoid (GC) production could partly explain ob-
served discrepancies in outcome for patients with 
AAD. Clinical experience shows great differences in 
dosage needs for GC replacement therapy, and not all 
patients require mineralocorticoid (MC) replacement 
(5). Moreover, 50% of patients with AAD have never 
experienced an adrenal crisis, and 10% have never re-
quired extra GC doses (6). Finally, there are large vari-
ations in self-assessed health-related quality of life 
(HRQoL) in AAD that could potentially be attributed 
to residual production (7, 8).
Here, we aimed to determine the frequency of re-
sidual corticosteroid production in established AAD and 
to examine the clinical features of residual production.
Material and Methods
Participants
We recruited study participants among patients enrolled 
in the Norwegian Registry of Organ-Specific Autoimmune 
Diseases, the Swedish Addison Registry, and patients re-
ceiving follow-up at the endocrine center “Endokrinologie 
in Charlottenburg” in Berlin, Germany. Invitation let-
ters were sent to eligible candidates by mail or handed 
out at regular clinical visits. All included participants 
had confirmed autoimmune etiology with presence of 
21-hydroxylase antibodies, were prescribed GC replace-
ment therapy, and were between 18 and 75  years of age 
at screening. Exclusion criteria were diabetes mellitus type 
1, cancer, severe organ failure, pregnancy, lactation, and 
current use of medications with known pharmaceutical 
interactions with adrenocortical hormones (antiepileptics, 
rifampicin, St John's wart). Any comorbidity had to be 
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Only patients on hydrocortisone or cortisone acetate re-
placement therapy were included. Patients previously using 
dual-release hydrocortisone were switched to cortisone 
acetate or hydrocortisone at least 1 week prior to blood sam-
pling. Any dehydroepiandrosterone treatment was paused for 
at least 1 week; alternatively androgen measurements were 
excluded from statistical analyses. Use of prednisolone or 
exogenous GCs on indication(s) other than adrenal insuffi-
ciency was paused for at least 3 months before blood sam-
pling. Patients using any other antihypertensive medication(s) 
than alpha blockers or calcium channel blockers, including 
diuretics, were excluded from analyses on electrolytes, renin, 
and MC hormones. Patients were instructed to abstain from 
grapefruit juice and licorice for at least 1 week and caffeinated 
drinks for at least 24 hours before blood sampling.
Study design
From September 2018 through January 2020 we per-
formed a 2-staged, cross-sectional multicenter clinical study 
comprising patients with AAD at 17 hospitals in Norway, 
Sweden, and Germany (Fig. 1). All authors vouch for the ac-
curacy of the data and for the fidelity of the study protocol.
Written informed consent was obtained from all parti-
cipants before study entry. At stage 1, we registered patient 
characteristics including age, sex, disease duration, medica-
tions, self-reported frequency of adrenal crises and infections, 
comorbidities, autoimmune polyendocrine syndrome type 2 
(APS2), disease-related symptoms, physical health (body mass 
index [(BMI], blood pressure, and presence of hyperpigmenta-
tion), and HRQoL questionnaires. All participants were pre-
scribed hydrocortisone for intramuscular use and instructed 
to take their replacement medications upon symptoms of 
precipitating adrenal crisis. Thereafter, patients returned on an 
agreed morning for medication fasting blood sampling after 
abstaining from GC and MC intake not later than 2 pm and 8 
am the day before, respectively.
At stage 2, patients with quantifiable levels of serum cor-
tisol and 11-deoxycortisol and/or quantifiable levels of serum 
aldosterone and corticosterone were asked to return for a 
standard 250  μg cosyntropin stimulation test (Synacthen). 
Blood samples were collected before (0 minutes) and 30 
and 60 minutes after intravenous injection of cosyntropin. 
Participants with a long commute to the hospital were offered 
to combine screening and stimulation testing on the same day. 
At Haukeland University Hospital, we also invited all patients 
without quantifiable serum cortisol and 11-deoxycortisol to 
serve as negative controls. Before testing, patients abstained 
from their steroid replacement therapy in the same manner 
as described above. A normal response was defined as peak 
cortisol exceeding 412 or 485 nmol/L after 30 or 60 minutes, 
respectively (9). The peak response was defined as the highest 
serum cortisol value recorded at either 30 or 60 minutes.
Outcomes
The primary endpoint was frequency of residual GC and/ 
or MC production in patients with AAD. Secondary endpoints 
included comparison of patients with and without residual 
GC and/or MC production with regards to patient character-
istics including age, sex, disease duration, steroid replacement 
therapy, peak cortisol in cosyntropin testing, frequency of ad-
renal crises and infections, physical health (BMI, blood pres-
sure, presence of hyperpigmentation), and HRQoL.
Laboratory tests
Routine blood tests were analyzed locally: hemoglobin, 
glycated hemoglobin, thyroid-stimulating hormone, free thy-
roxine, cobalamin, ferritin, creatinine, sodium, potassium, 
cholesterol, high-density lipoprotein cholesterol, low-density 
lipoprotein cholesterol, triglycerides, thyroid peroxidase anti-
bodies, ACTH, and plasma renin concentration (PRC). Levels of 
ACTH exceeding the upper limit of quantification were plotted 
as 278 pmol/L. All corticosteroid analyses were performed 
at Haukeland University Hospital by a liquid chromatog-
raphy–tandem mass spectroscopy (LC-MS/MS) assay further 
developed from and expanded on a published method (10), 
measuring cortisol, 11-deoxycortisol, 21-deoxycortisol, corti-
sone, 18-oxocortisol, 18-hydroxycortisol, tetrahydrocortisol, 
allo-tetrahydrocortisol, tetrahydrocortisone, allo-
tetrahydrocortisone, aldosterone, corticosterone, 11-deoxy-
corticosterone, androstendione, testosterone, epitestosterone, 
dihydrotestosterone, and progesterone (Fig. 2). The lower limit 
of quantification for each corticosteroid is listed in Table 1.
Defining residual corticosteroid production
There is no consensus on the definition of residual cortico-
steroid production, and no marker of endogenous GC or MC 
production exists. Here, we defined residual GC production 
as quantifiable levels of serum cortisol (>0.914 nmol/L) and 
11-deoxycortisol (>0.114 nmol/L) and residual MC produc-
tion as quantifiable levels of serum aldosterone (> 8 pmol/L) 
and corticosterone (>0.114 nmol/L). All blood samples were 
obtained in the morning after at least 18 hours without hydro-
cortisone or cortisone acetate and at least 24 hours without 
fludrocortisone (FC).
HRQoL questionnaires
All patients filled out 1 generic (RAND-36) (11) and 1 
AAD-specific (AddiQoL) (12) questionnaire assessing HRQoL. 
RAND-36 is a license free version of the Short Form 36-item 








niversitetsbiblioteket i Bergen user on 21 D
ecem
ber 2020
doi:10.1210/clinem/dgaa256 https://academic.oup.com/jcem  2433
physical functioning, role limitations caused by physical 
health problems, role limitations caused by emotional prob-
lems, social functioning, general mental health, vitality, bodily 
pain, and general health. Scoring of RAND-36 is a 2-step pro-
cess. First, precoded numeric values are recorded to a number 
between 0 and 100 where a higher score represents a better 
health state. In the second step, items belonging to the same 
health concept are averaged to create 1 of the 8 total scores 
(11). AddiQoL has been validated and translated into several 
languages including Norwegian, Swedish, and German (12). 
The questionnaire contains 30 items divided into 4 domains: 
fatigue, emotional well-being, adrenal insufficiency-related 
symptoms, and miscellaneous (sexuality, sleep, and impact 
of intercurrent disease). Every item has 6 scoring categories 
scored as 1, 2, 2, 3, 3, and 4 for positive statements and 4, 3, 
3, 2, 2, and 1 for negative statements. A total score is gener-
ated by adding the score of individual items, producing a total 
score ranging from 30 to 120 where a higher score indicates a 
more favorable HRQoL. A missing individual item score can 
be replaced by the mean score from the rest of the items in the 
same subdimension.
Statistics
We report the primary endpoint as absolute numbers and 
percentages. Descriptive statistics and secondary endpoints 
are presented as numbers and percentages for categorical 
data and as medians and range [minimum to maximum] 
or as means and standard deviations (± SD) for continuous 
variables. To compare subgroups, we used independent sam-
ples t test, Mann-Whitney independent sample U test, and 
chi-square test, as appropriate. Correlations were explored 
using the Spearman rank correlation. Binary logistic re-
gression was performed to assess the impact of key patient 
characteristics on the likelihood of having residual GC or MC 
production. Nine clinically relevant variables were included: 
age at diagnosis, sex, disease duration, history of adrenal crisis 
ever, BMI, hydrocortisone-equivalent dosage (mg cortisone 
acetate/1.25 = mg hydrocortisone), FC dosage, AddiQoL-30 
score, and plasma ACTH (for GC) or PRC (for MC). 
Preliminary analyses were conducted to ensure no violation of 
the assumption of multicollinearity. Results are presented as 
odds ratio (OR) and 95% confidence interval (CI). To reduce 
the risk of type I error, the alpha value was set to 0.01.
Ethics
Ethical approval was granted from all participating coun-
tries before study start, by the Regional Ethical Committee 
of South-East Norway (permit no.  2018/751/REK Sør-Øst), 
of Stockholm, Sweden (permit no.  2018/2247-32), and of 
Berlin, Germany (permit no. Eth-47/18). The study was re-
gistered at clinicaltrials.gov (ClinicalTrials.gov Identifier: 
NCT03793114) and conducted in agreement with local 
and international guidelines and regulations, including the 
Declaration of Helsinki (2013 version) and the principles of 
good clinical practice (CPMP/ICH/135/95).
Results
Stage 1: Frequency and clinical characteristics of 
residual corticosteroid production
Frequency of residual production. We included 197 
patients with AAD. Five patients declined to proceed to 
medication fasting blood sampling and were excluded 
from the study. Baseline characteristics for the remaining 
Figure 2. Synthesis of adrenocortical steroids. The 3 main adrenocortical steroids (aldosterone, cortisol, and dihydroepiandrostendione sulphate) 
are shown in circles, while precursor steroids and metabolites are shown in rectangles. Bold borders mark steroids analyzed in this study. 
Cortisol and 11-deoxycortisol define residual glucocorticoid production and are marked in red. Aldosterone and corticosterone define residual 
mineralocorticoid production and are marked in blue. Red and blue arrows mark the enzymatic reactions for activation of cortisol and aldosterone, 
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192 patients are presented in Table 2. The medication 
fast was generally well-tolerated, with only a few indi-
viduals reporting increased tiredness and/or headache at 
blood sampling. Fifty-eight (30.2%) patients had quan-
tifiable levels of serum cortisol and 11-deoxycortisol 
(Fig. 3A, B), and 26 (13.5%) patients had quantifiable 
levels of serum aldosterone and corticosterone (Fig. 3C, 
D). In 24 (12.5%) patients, all 4 hormones were quan-
tifiable. There was a strong positive correlation between 
serum cortisol and 11-deoxycortisol levels (r = 0.796; 
P < 0.001) (Fig. 4A), as well as for aldosterone and cor-
ticosterone (r = 0.605; P < 0.001) (Fig. 4B).
Residual GC production. Thirty-three (56.9%) of the 
58 patients with residual GC production were men 
(X2(1, N = 192) = 9.405; P < 0.002). Patients with re-
sidual GC production also had significantly shorter 
disease duration (median 6 [0-44] vs 13 [0-53] years; 
P < 0.001) and higher levels of all adrenal steroids ex-
cept 18-oxo-cortisol (Table  1). These findings were 
supported by binary logistic regression, where male 
sex (OR 5.9; 95% CI, 2.4-14.5; P < 0.001) and short 
disease duration both predicted residual GC produc-
tion (OR 0.95; 95% CI, 0.91-0.98; P < 0.006). As a 
whole, the regression model explained between 18.5% 
and 26.3% of the variance in residual GC production 
status and correctly classified 75.3% of the cases (X2(9, 
N = 182) = 37.308; P < 0.001).
The highest recorded serum cortisol value 
(507  nmol/L) was found in a 68  year-old woman. At 
time of diagnosis 10  years earlier, she used estrogen 
replacement therapy. She was admitted due to weight 
Table 1. Corticosteroids in Patients with and Residual Glucocorticoid Production
Median (minimum-maximum)
Corticosteroid N LLoQ GC+ GC– P
18-oxo-cortisol (nmol/L) 192 0.046 0.00 (0.00-0.30) 0.00 (0.00-1.27) <0.001a
18-OH-cortisol (nmol/L) 192 0.046 0.26 (0.00-0.28) 0.00 (0.00-0.20) <0.001a
Aldosterone (pmol/L)b 191 8.0 0 (0-220) 0 (0-25) <0.001a
Cortisone (nmol/L) 191 0.914 10.21 (1.63-46.88) 0.00 (0.00-4.16) <0.001a
Cortisol (nmol/L)c 192 0.914 57.28 (5.48-507.04) 0.98 (0.00-27.18) <0.001a
DHEAS (nmol/L) 176 22.9 432.69 (25.07-2400.12) 0.00 (0.00-1459.51) <0.001a
21-deoxycortisol (nmol/L) 192 0.023 0.032 (0.00-14.50) 0.00 (0.00-1.05) <0.001a
Corticosterone (nmol/L) 191 0.114 3.50 (0.00-50.84) 0.00 (0.00-2.67) <0.001a
Allo-tetrahydrocortisol (nmol/L) 191 0.114 2.14 (0.00-21.54) 0.00 (0.00-1.56) <0.001a
11-deoxycortisol (nmol/L) 192 0.114 0.60 (0.12-2.87) 0.00 (0.00-0.21) <0.001a
Tetrahydrocortisol (nmol/L) 192 0.343 1.57 (0.00-17.06) 0.00 (0.00-2.84) <0.001a
Allo-tetrahydrocortisone (nmol/L) 192 0.343 0.00 (0.00-1.39) 0.00 (0.00–0.42) <0.001a
Tetrahydrocortisone (nmol/L) 192 0.114 0.95 (0.00–9.82) 0.00 (0.00-0.69) <0.001a
Androstendione (nmol/L) 175 0.023 0.92 (0.00-4.51) 0.440 (0.00-4.04) <0.001a
11-deoxycorticosterone (nmol/L) 191 0.023 0.12 (0.00-0.94) 0.00 (0.00-0.16) <0.001a
Testosterone (nmol/L) 176 0.023 7.74 (0.04-27.39) 0.34 (0.00-30.57) <0.001a
DHEA (nmol/L) 174 0.617 0.71 (0.00-4.33) 0.34 (0.00-1.97) <0.001a
17-hydroxy-progesterone (nmol/L) 192 0.114 2.90 (0.00-49.29) 0.73 (0.00-894.6) <0.001a
Epitestosterone (nmol/L) 176 0.023 0.06 (0.00-0.31) 0.00 (0.00-0.46) 0.008a
Dihydrotestosterone (nmol/L) 176 0.206 0.57 (0.00-2.50) 0.00 (0.00-2.61) 0.020
Progesterone (nmol/L) 191 0.114 0.18 (0.00-81.35) 0.00 (0.00-48.27) <0.001a
GC+, residual glucocorticoid production; GC–, no residual glucocorticoid production; 
Abbreviations: DHEA, dehydroepiandrosterone; DHEAS, dehydroepiandrosterone sulfate; GC, glucocorticoid; LLoQ, lower limit of quantification. 
aStatistically significant at 0.01 level.
bTo convert serum aldosterone values (pmol/L) to ng/dL, divide by 27.7.
cTo convert serum cortisol values (nmol/L) to μg/dL, divide by 27.6.
Table 2. Patient characteristics (n = 192)
Characteristics 
Number (%) or Median  
(range) or Mean (±SD)
Female  116 (60.4) 
Age (years) 48.3 ± 13.0
Age at diagnosis, years 33.5 (11-64)
Disease duration, years 11 (0-53)
APS 2, n (%) 109 (56.8) 
Use of hydrocortisone, n (%) 74 (38.5)
Use of cortisone acetate, n (%) 118 (61.5)
Hydrocortisone equivalent doses, 
mg/day
20 (7.5-50.0)
Use of fludrocortisone, n (%) 189 (98.4)
Total fludrocortisone dose, mg/day 0.10 (0.03-0.30)
Women using DHEA, n (%) 16 (13.8)
Body mass index, kg/cm2 24.4 (16.6-38.3)
Systolic blood pressure, mmHg 120 (84-169)
Diastolic blood pressure, mmHg 76 (50-95)
Hyperpigmentation, n (%) 100 (52.4)
Abbreviations: APS, autoimmune polyendocrine syndrome; DHEA, 
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loss, stomach pain, nausea and vomiting and had 
hyponatremia (124  mmol/L). Although serum cor-
tisol was within normal range, plasma ACTH was 
elevated at 294 pmol/L, the maximal cortisol peak at 
cosyntropin test was suboptimal at 407 nmol/L, and the 
21-hydroxylase autoantibody index was clearly elevated. 
Her symptoms were relieved after initiation of replace-
ment therapy with hydrocortisone and FC. In addition, 
ACTH analyses, cosyntropin tests, and 21-hydroxylase 
autoantibody assays have been performed at several oc-
casions after diagnosis and remained pathological. The 
patient reported several adrenal crises since receiving 
the diagnosis in 2010, including 1 incident last year due 
to gastrointestinal infection with vomiting and diarrhea.
Residual MC production. On group level, patients 
with MC residual production had shorter disease 
duration (median 5.5 [0.5-26.0] vs 13 [0-53] years; 
P< 0.004), lower FC replacement dosage (median 0.075 
[0.050-0.120] vs 0.100 [0.028-0.300] mg; P < 0.005), 
higher PRC (median 179 [22-915] vs 47.5 [0.6-658.0] 
mU/L; P < 0.001), and higher levels of all but 5 steroids 
(18-oxo-cortisol, allo-tetrahydrocortisone, testosterone, 
epitestosterone, dihydrotestosterone; data not shown). 
For binary logistic regression on residual MC produc-
tion, only PRC and disease duration significantly con-
tributed to the model. The likelihood of residual MC 
production decreased with disease duration (OR 0.89; 
CI 95%, 0.82-0.96; P< 0.003) and slightly increased 
with higher PRC (OR 1.005; CI 95%, 1.002-1.008; 
P < 0.001. In sum, the regression model explained be-
tween 18.9% and 35.4% of the variance and correctly 
classified 90.8% of the cases (X2(9, N = 173) = 36.197; 
P < 0.001).
The highest serum aldosterone level recorded (217 
pmol/L) was found in a 23-year-old woman. Her plasma 
renin concentration exceeded the upper limit of detec-
tion (>500 mU/L). The patient also presented with a 
high cortisol (340 nmol/L) and did not use oral contra-
ceptive pills or estrogen. Of note, the patient had experi-
enced adrenal crisis twice since receiving the diagnosis 
in 2013 and suffers concomitant hypothyroidism, celiac 
disease, vitamin B12 deficiency, and previously Graves 
disease. At time of diagnosis, she fulfilled the diagnostic 
criteria for AD, with morning cortisol in the lower ref-
erence range, elevated ACTH level, and clearly elevated 
index of 21-hydroxylase autoantibodies.
Combined residual GC and MC production. 
Twenty-four patients had quantifiable levels of cor-
tisol, 11-deoxycortisol, aldosterone, and corticosterone. 
They had significantly shorter disease duration (me-
dian 5.5 [0.5-26.0] vs 13.5 [0.0-53.0] years; P < 0.002), 
higher PRC (median 152 [22-915] vs 46 [1-658] mU/L; 
P < 0.001), and higher levels of all but 3 steroids (tes-
tosterone, epitestosterone, dihydrotestosterone; data 
not shown) compared with patients with no residual 
production. Individual patient data are presented in 
Table 3.
Figure 3. Stage 1: Corticosteroid levels in patients with residual 
glucocorticoid or mineralocorticoid production. The line marks 
median corticosteroid values and the whiskers the interquartile 
range. Triangles mark patients with both glucocorticoid and 
mineralocorticoid residual production. The patients with the highest 
quartile of 11-deoxycortisol and corticosterone values are marked 
in red and blue, respectively. (A) Serum cortisol at baseline (n = 58). 
(B) Serum 11-deoxycortisol values at baseline (n = 58). (C) Serum 
aldosterone values at baseline (n = 26). (D) Serum corticosterone 
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Residual production and clinical characteristics. 
On group level, all routine laboratory values were within 
the reference intervals (Table 4). Patients with residual 
GC and/or MC production did not differ significantly 
from those without residual production regarding fre-
quency of adrenal crises, number of infections the 
previous year, APS2, disease-related symptoms, hydro-
cortisone equivalent dosage, physical health, or HRQoL 
scores (AddiQoL and RAND-36) (Table 4).
Stage 2: Cosyntropin test
In total, 55 patients with residual GC production 
underwent the cosyntropin test. Three patients with 
quantifiable cortisol and 11-deoxycortisol at baseline 
declined. The screening results of residual GC produc-
tion were verified in all but 5 patients. These patients 
were excluded from statistical analyses on cosyntropin 
test results. The remaining 50 patients reached a median 
peak cortisol of 75 [9-419] nmol/L (Fig. 5A), confirming 
the diagnosis of adrenal insufficiency. Higher serum 
cortisol levels at 0 minutes and lower plasma ACTH 
levels strongly correlated with peak cortisol (r = 0.989; 
P < 0.001, and r = –0.487; P < 0.001, respectively) 
(Figs. 5B and 5C).
The cosyntropin test was also performed in 2 patients 
with isolated residual MC production at screening, but 
upon testing aldosterone, it was only quantifiable for 1 
of them. For this patient, aldosterone levels remained 
unchanged at 40 pmol/L throughout the test.
Twenty patients without quantifiable levels of cor-
tisol and 11-deoxycortisol and/or aldosterone and 
corticosterone at stage 1 were included as controls. At 
cosyntropin testing, serum cortisol was barely quantifi-
able in 10 of the controls but remained unquantifiable 
in the other 10 controls. Two controls also had barely 
quantifiable levels of serum corticosterone, but none 
had quantifiable levels of serum 11-deoxycortisol or 
aldosterone.
Discussion
We found residual GC production in one-third of pa-
tients with established AAD, more common in men than 
in women. Patients with residual production had overall 
shorter disease duration, but several had a history of 
AAD lasting for decades. More than 1 of 7 patients had 
residual MC production. These were characterized by 
shorter disease duration, lower FC dosage, and higher 
plasma renin concentrations compared with those 
without residual MC production. No significant associ-
ations were found between residual corticosteroid pro-
duction and a number of clinical parameters. To date, 
this is the largest study on residual production in AAD, 
conducted on a representative study cohort from 17 cen-
ters in 3 countries. We are confident that the diagnosis 
of AAD is correct in all included patients as we required 
documented presence of 21-hydroxylase antibodies and 
chronic need for GC replacement therapy for inclusion.
There is no established definition of residual cor-
ticosteroid production. LC-MS/MS enables measure-
ment of minute quantities of cortisol and aldosterone; 
however, the clinical effect of very low cortisol and al-
dosterone concentrations is uncertain. We believe that 
merely evaluating serum cortisol levels would result in a 
falsely high prevalence of residual GC production, as up 
to half of the bioavailable cortisol stems from cortisone 
regenerated by 11-β-hydroxysteroid dehydrogenase 
type 1 (13). In addition, it is important to discriminate 
between endogenous and exogenous cortisol in these 
patients who use GC replacement therapy. This could 
Figure 4. Correlation between corticosteroids. (A) Correlation between serum cortisol and 11-deoxycortisol (P < 0.001). (B) Correlation between 
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in part be avoided by having patients abstain from GC 
replacement therapy for a longer period of time but 
would put them at risk of developing an adrenal crisis. 
Concerning residual MC production, we are not aware 
of any bidirectional pathways in aldosterone metab-
olism. Furthermore, FC is a synthetic MC and does not 
interfere with aldosterone measurements on LC-MS/MS 
(14). In the present study, patients were asked to abstain 
from GC and MC replacement therapy for at least 18 
and 24 hours, respectively, before sample collection. To 
further ensure that the measured hormones indeed rep-
resented de novo synthesis of corticosteroids, we chose 
to include precursors for the definitions of residual GC 
and MC production. Importantly, the enzymes involved 
in conversion of the precursors to the active substances 
are considered unidirectional (15), precluding any syn-
thesis of precursors from cortisol or aldosterone. This 
was well illustrated by 1 of the study participants who 
had a serum cortisol level of 797 nmol/L but no quanti-
fiable 11-deoxycortisol. Later, it become known that she 
had taken her morning dose of cortisone acetate before 
the blood sampling but had forgotten to mention it. The 
patient was therefore excluded. In patients with residual 
production, we found that median and range values of 
11-deoxycortisol and corticosterone corresponded with 
values found in healthy controls (16), suggesting that 
these are suitable as biomarkers of residual production.
We were surprised to detect a clear overweight of men 
with residual GC production, despite women constituting 
the majority of our study cohort. This may be due to sex-
related disparities in immunology as well as susceptibility 
to autoimmune disease (17). It has been suggested that 
inherent sex differences in adrenal gland tissue renewal 
could be involved (18). Indeed, in mice, the turnover rate 
for adrenocortical tissue is 3 times higher in females com-
pared with males, and capsular stem cells only contribute 
to tissue renewal in females, not in males (18). Whether 
these findings are relevant for humans is not known, and 
highlights the need for future studies to explore the im-
pact of sex on the trajectory of autoimmune adrenalitis.
As expected, the patients with GC and/or MC re-
sidual production had shorter median disease duration. 
However, there was a wide range in disease duration 
among the patients with residual production, extending 
up to 26 years for MC and 44 years for GC residual 
production, arguing against the common assumption 
that AAD inevitably leads to loss of all adrenal cortico-
steroid production. Concurrently, it raises questions 
of how and why the intensity and extent of the auto-
immune attack seem to differ between individuals.
Regarding steroid replacement therapy, we found sig-
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MC production. This could, of course, be due to lower 
replacement needs. As these participants also had higher 
levels of plasma renin concentration, one could specu-
late if greater renin exposure via an activated renin-
angiotensin-aldosterone system may stimulate MC 
production in remnants of the zona glomerulosa. We 
did not find any association between residual cortico-
steroid production and hydrocortisone-equivalent dos-
ages. This might be masked by the fact that GC receptor 
polymorphisms influence the GC replacement dose (19). 
In addition, there is currently no available biomarker to 
guide optimization of GC replacement treatment. When 
evaluating FC dosages, the physician is aided by the 
patient’s blood pressure, electrolyte levels, and plasma 
renin concentration (20). For GC therapy, however, 
surveillance relies upon more vague clinical signs and 
the patient’s subjective health status (21). Therefore, 
we cannot rule out that patients with residual GC pro-
duction receive unnecessarily high GC dosages. If true, 
residual production could put patients at risk of dele-
terious health effects due to GC excess, including car-
diovascular disease (22), infections (23), and premature 
death (24). Whether residual production enables safe 
dose reductions should be explored in further studies.
Of note, we found no differences in frequency of ad-
renal crises, infections, APS2, disease-related symptoms, 
physical health, or HRQoL in patients with and without 
residual production of adrenal corticosteroids. An ob-
vious explanation is, of course, that no such links exist. 
Yet, as with any exploratory study, we must acknow-
ledge that our chosen methods may not have been ideal 
for evaluating the clinical significance of residual GC and 
MC production. Furthermore, quantifiable levels of ad-
renal corticosteroids may not represent clinically signifi-
cant values. Inaccuracies due to recall bias must also be 
considered, especially for the frequencies of adrenal crises 
and infections that were self-reported by the patients.
In line with previous studies, none of the patients in the 
current study had a normal response to the cosyntropin 
test (2, 4, 25, 26). Still, patients with higher cortisol levels 
before injection of cosyntropin reached significantly 
higher peak cortisol, suggesting a greater stimulatory po-
tential. Indeed, in attempts to regenerate adrenocortical 
function in AAD by rituximab and/or tetracosactide, 
lasting recovery has only been reported in 2 patients 
with cosyntropin-stimulated peak cortisol of 219 and 
235 nmol/L before treatment initiation (4, 25, 26).
Unfortunately, our study design did not allow us to an-
swer the compelling questions on the nature and origin of 
residual production in AAD. In order to investigate possible 
heterogeneity in disease development and adrenal plasticity, 
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individuals to be assessed at baseline and followed annu-
ally. Such a study could ascertain whether certain AAD 
subpopulations are more resistant to immune-mediated 
destruction, perhaps by harboring other human leukocyte 
antigen genotypes than patients without residual production, 
or if the intensity of autoimmune destruction may vary over 
time allowing regeneration of steroid-producing cells.
In our opinion, remnants of functional adrenocortical 
tissue are the most probable origin of residual produc-
tion. We suggest 2 possible mechanisms: Either areas in 
the adrenal cortex have been spared from autoimmune 
attack or adrenocortical cells could be replenished by dif-
ferentiation of subcapsular stem cells (27). Both are in line 
with observations in autoimmune type 1 diabetes where 
pancreatic infiltration of immune cells is not always uni-
form but may be patchy and leave subsets of pancreatic 
islets unaffected (28). Indeed, recent reports suggest that 
residual beta cell capacity may be present in one-third of 
patients with longstanding type 1 diabetes (28).
An alternative explanation is extra-adrenal produc-
tion. The observed male preponderance in residual GC 
production opens for a tantalizing link to hormone-
producing testicular adrenal rest tumors (TARTs), as 
seen in approximately 40% of men with congenital 
adrenal hyperplasia (29). However, a recent ultrasono-
graphic screening of 14 men with Addison disease 
could not detect any cases of TART (30). Moreover, if 
TARTs indeed were the true sources of residual produc-
tion, there would still be the question on how cortisol-
producing cells evade the autoimmune attack, as the 
Leydig cells are located outside the blood-testis barrier 
(31). In conclusion, one-third of patients with auto-
immune Addison disease still produce GCs and MCs 
even years after the diagnosis, more commonly observed 
in men in our cohort. These findings challenge our cur-
rent understanding of the natural course of the disease.
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